Shots:

• Under the amended agreement- Intellia to receive ~$70M as up front with an additional equity investment of $30M at $32.42/ share. The 2016 collaboration get extended until April 2024 with Regeneron having an option to renew for an additional 2years
• Regeneron will get rights to discover & develop CRISPR/Cas9-based therapies for an additional 5 in vivo liver targets- for a total of up to 15 targets. The companies will jointly research these in vivo targets- these targets may be developed by Regeneron or Intellia or co-developed under certain conditions
• As per the 2016 agreement- Intellia will receive royalties and milestones for the in vivo products it independently develops while Regeneron will get a royalty-bearing non-exclusive license to certain Intellia’s IP to develop and commercialize up to 10 ex vivo CRISPR/Cas9 products in defined cell types.  Additionally- the two companies will co-develop potential products for the hemophilia A and B

Click here to read full press release/ article | Ref: Businesswire | Image: Regeneron